No Data
Viasheng Pharmaceutical (02561) roadshow summary: Innovative verification technology supports the enhancement of commercialization certainty for the product pipeline.
Recently, Weisheng Pharmaceutical (02561) had in-depth discussions with investors regarding the company's fundamentals and the development status of its core product pipeline.
Major bank rating | Morgan Stanley: Initiated a Shareholding rating for Weisheng Pharmaceutical (2561.HK) with a Target Price of HKD 80.
Morgan Stanley's first coverage research report indicates that Weisheng Pharmaceutical (2561.HK) ("Weisheng") is a strong growth-oriented company focused on endocrine treatment. Its unique origin background enables it to accelerate the advancement of its product pipeline, which has been validated overseas, and thereby capture the significant growth potential of the metabolic disease market in China without incurring the traditional costs of licensing for introduction.
VISEN PHARMA-B: 2024 Annual Report
Wesheng Pharmaceutical-B (02561): Stabilization price action, end of stabilization period, and expiration of the over-allotment option.
Weisheng Pharmaceutical-B (02561) announced that the stabilization period related to the Global offering ended in April 2025...
Hong Kong stocks movement | Wei Sheng Pharmaceutical-B (02561) rose over 4% in early trading, core product Longpei Growth Hormone is expected to be approved in 2025.
Weisheng Pharmaceutical-B (02561) rose more than 4% in the morning session, and as of the time of writing, it has increased by 3.1%, priced at 54.8 Hong Kong dollars, with a transaction amount of 1.4565 million Hong Kong dollars.
VISEN PHARMA-B: FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024
